Patents by Inventor Santosh Vani

Santosh Vani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOP2A inhibition by temozolomide and its predictive value of GBM patients survival
    Patent number: 9487818
    Abstract: The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: November 8, 2016
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Somasundaram Kumaravel, Arivazhagan Arimappamagan, Kandavel Thennarasu, Alangar Sathyaranjandas Hegde, Ashwathnarayana Chandramouli, Santosh Vani, Paturu Kondaiah, Satyanarayana Rao Manchanahalli Rangaswamy
  • TOP2A INHIBITION BY TEMOZOLOMIDE AND ITS PREDICTIVE VALUE OF GBM PATIENTS SURVIVAL
    Publication number: 20130280707
    Abstract: The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.
    Type: Application
    Filed: September 22, 2011
    Publication date: October 24, 2013
    Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Somasundaram Kumaravel, Arivazhagan Arimappamagan, Kandavel Thennarasu, Alangar Sathyaranjandas Hegde, Ashwathnarayana Chandramouli, Santosh Vani, Paturu Kondaiah, Satyanarayana Rao Manchanahalli Rangaswamy